Abstract
There is increasing evidence supporting potential roles of aldosterone in the pathogenesis of vascular injury. The present study aimed to determine the involvement of Rho-kinase in aldosterone-induced vascular smooth muscle cell (VSMC) remodeling. In cultured rat VSMC, the effects of aldosterone on Rho-kinase activity, the reorganization of the cytoskeleton and cellular migration were examined. Aldosterone (1 nmol/ L) significantly increased phosphorylation of myosin phosphate target subunit-1 (MYPT1), a marker of Rhokinase activity, and the amount of GTP-Rho with a peak at 90 min in VSMC. Aldosterone also stimulated VSMC stress fiber formation and migration. These effects of aldosterone were markedly attenuated by pretreatment with eplerenone (10 μmol/L), a selective mineralocorticoid receptor antagonist, or Y27632 (10 μmol/L), a specific Rho-kinase inhibitor. These findings indicate that Rho-kinase is involved in the pathogenesis of aldosterone-induced VSMC remodeling.
Similar content being viewed by others
Article PDF
References
Nishimura M, Uzu T, Fujii T, et al: Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261–266.
Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717.
Pitt B, Remme W, Zannad F, et al: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.
Takeda Y : Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004; 217: 75–79.
Yoshida K, Kim-Mitsuyama S, Wake R, et al: Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005; 28: 447–455.
Muiesan ML, Rizzoni D, Salvetti M, et al: Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 2002; 20: 1439–1444.
Park JB, Schiffrin EL : ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone- infused rats. Hypertension 2001; 37: 1444–1449.
Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M : Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106: 2848–2853.
Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL : Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004; 43: 1252–1257.
Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr : Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451–458.
Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A : Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001; 104: 467–472.
Brown JH, Del Re DP, Sussman MA : The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006; 98: 730–742.
Loirand G, Guerin P, Pacaud P : Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322–334.
Moriki N, Ito M, Seko T, et al: RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 2004; 27: 263–270.
Hattori T, Shimokawa H, Higashi M, et al: Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 2004; 94: 46–52.
Higashi M, Shimokawa H, Hattori T, et al: Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93: 767–775.
Kanda T, Hayashi K, Wakino S, et al: Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension 2005; 45: 724–729.
Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H : Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal–regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/ salt-induced hypertensive rats. Hypertens Res 2005; 28: 925–936.
Sun GP, Kohno M, Guo P, et al: Involvements of Rhokinase and transforming growth factor β pathways in aldosterone- induced renal injury. J Am Soc Nephrol 2006; 17: 2193–2201.
van Nieuw Amerongen GP, van Hinsbergh VW : Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol 2001; 21: 300–311.
Ishizawa K, Izawa Y, Ito H, et al: Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogenactivated protein kinase 1 activation. Hypertension 2005; 46: 1046–1052.
Kyaw M, Yoshizumi M, Tsuchiya K, et al: Src and Cas are essentially but differentially involved in angiotensin II– stimulated migration of vascular smooth muscle cells via extracellular signal–regulated kinase 1/2 and c-Jun NH2-terminal kinase activation. Mol Pharmacol 2004; 65: 832–841.
Salhia B, Rutten F, Nakada M, et al: Inhibition of Rhokinase affects astrocytoma morphology, motility, and invasion through activation of Racl. Cancer Res 2005; 65: 8792–8800.
Rupérez M, Rodrigues-Díez R, Blanco-Colio LM, et al: HMG-CoA reductase inhibitors decrease angiotensin II– induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 2007; 50: 377–383.
Adami R, Cintio O, Trombetta G, Choquet D, Grazi E : On the stiffness of the natural actin filament decorated with alexa fluor tropomyosin. Biophys Chem 2003; 104: 469–476.
Sato A, Saruta T, Funder JW : Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006; 29: 211–216.
Ishizaki T, Uehata M, Tamechika I, et al: Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000; 57: 976–983.
Safar ME, Henry O, Meaume S : Aortic pulse wave velocity: an independent marker of cardiovascular risk. Am J Geriatr Cardiol 2002; 11: 295–298.
Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK : Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem 2001; 276: 341–347.
Kang DH, Park SK, Lee IK, Johnson RJ : Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553–3562.
Nishiguchi F, Fukui R, Hoshiga M, et al: Different migratory and proliferative properties of smooth muscle cells of coronary and femoral artery. Atherosclerosis 2003; 171: 39–47.
Kishi H, Bao J, Kohama K : Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J Biochem (Tokyo) 2000; 128: 719–722.
Kiian I, Tkachuk N, Haller H, Dumler I : Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/ PI3-K signalling pathway. Thromb Haemost 2003; 89: 904–914.
Seasholtz TM, Majumdar M, Kaplan DD, Brown JH : Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999; 84: 1186–1193.
Fu M, Zhang J, Tseng YH, et al: Rad GTPase attenuates vascular lesion formation by inhibition of vascular smooth muscle cell migration. Circulation 2005; 111: 1071–1077.
Liu Y, Suzuki YJ, Day RM, Fanburg BL : Rho kinase- induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 2004; 95: 579–586.
Menard J, Gonzalez MF, Guyene TT, Bissery A : Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006; 24: 1157–1163.
Sato A, Saruta T : Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303–310.
Takeda Y : Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens Res 2004; 27: 781–789.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miyata, K., Hitomi, H., Guo, P. et al. Possible Involvement of Rho-Kinase in Aldosterone-Induced Vascular Smooth Muscle Cell Remodeling. Hypertens Res 31, 1407–1413 (2008). https://doi.org/10.1291/hypres.31.1407
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1407
Keywords
This article is cited by
-
Danhong injection reduces vascular remodeling and up-regulates the Kallikrein-kinin system in spontaneously hypertensive rats
Scientific Reports (2017)
-
The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes
Diabetology & Metabolic Syndrome (2014)
-
Direct Role for Smooth Muscle Cell Mineralocorticoid Receptors in Vascular Remodeling: Novel Mechanisms and Clinical Implications
Current Hypertension Reports (2014)
-
Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho-Associated Kinase Activity in Patients With Hypertension
Clinical Pharmacology & Therapeutics (2012)
-
Effects of Spironolactone on Cerebral Vessel Structure in Rats With Sustained Hypertension
American Journal of Hypertension (2011)